Exelixis
EXELExelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
© Wikipedia /
Creative Commons CC-BY-SA 3.0 more at Wikipedia
Insider trades and stock quote 2023-2025
All insider trades at Exelixis
Subscribe RSS| Date | Type | Insider | Position | Ø-Price | Volume |
|---|---|---|---|---|---|
| 5/1/2025 | Sell | Aftab, Dana | CSO/EVP Disc & Trans Research | $39.0 | $58,812 |
| 3/3/2025 | Sell | Haley, Patrick J. | EVP, Commercial | $38.8 | $388,000 |
| 2/28/2025 | Sell | Wyszomierski, Jack L. | Director | $37.8 | $331,430 |
| 2/28/2025 | Sell | Smith, Julie | Director | $37.6 | $725,840 |
| 2/27/2025 | Sell | Smith, Julie | Director | $38.1 | $2,078,619 |
All information without guarantee! No recommendation/consultation!
© U.S. Securities and Exchange Commission (SEC)